Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

DiaMedica DMAC DM199 Phase 2 updates extend runway and de-risk pipeline

Aug 10, 2026, 4:34 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The combination of positive Phase 2 topline signals (PE), first FGR cohort enrollment results, regulatory progress (Health Canada IND-related steps), and a clear cash runway through 2027 builds multiple near-term catalysts that could drive re-rating of DMAC on progress toward Phase 3 readouts.

AI summary

What happened, with direct paths to the underlying reporting

DiaMedica released a multi-program update for DM199, highlighting the completion of the first fetal growth restriction cohort and a September KOL call for topline results. Phase 2 preeclampsia topline data show meaningful BP reductions, guiding mid-dose selection, while AIS ReMEDy2 is nearing an interim readout in early 2027 with broad site activation. With $43.5 million in cash and a runway through 2027, the company plans continued global expansion and IND progress in the U.S. and Canada.

First FGR DM199 cohort completed; KOL call scheduled in September; topline results due.
PE Phase 2 Part 1a topline shows meaningful SBP/DBP reductions; mid-dose guidance.
AIS ReMEDy2 Phase 2/3 interim readout expected early 2027; ~70 active sites.
Cash, cash equivalents and investments total $43.5 million; runway through 2027.
Health Canada authorizes global Phase 2 PE study; first patient expected Q4 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

DiaMedica DMAC DM199 Phase 2 updates extend runway and de-risk pipeline

DiaMedica to Report Q4 Earnings Amid Positive Phase 2 Study Clearance